Paediatr Perinat Epidemiol by Miller, Jessica E. et al.
Maternal Infections during Pregnancy and Cerebral Palsy: A 
Population-based Cohort Study
Jessica E. Millera, Lars Henning Pedersenc,d, Elani Strejaa, Bodil H. Bechd, Marshalyn 
Yeargin-Allsoppb, Kim Van Naarden Braunb, Diana E. Schendelb, Deborah Christensenb, 
Peter Uldalle,f, and Jørn Olsena,d
aDepartment of Epidemiology, Fielding School of Public Health, University of California, Los 
Angeles, CA
bNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control 
and Prevention, Atlanta, GA
cDepartment of Obstetrics and Gynecology, Institute of Clinical Medicine, Aarhus University, 
Aarhus, Denmark
dDepartment of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
eThe Danish Cerebral Palsy Registry, National Institute of Public Health, University of Southern 
Denmark, Copenhagen, Denmark
fPediatric Department, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Abstract
Background—Cerebral palsy (CP) is a common motor disability in childhood. We examined the 
association between maternal infections during pregnancy and the risk of congenital CP in the 
child.
Methods—Liveborn singletons in Denmark between 1997 and 2003 were identified from the 
Danish National Birth Registry and followed from 1 year of life until 2008. Redemption of 
antibiotics from the National Register of Medicinal Product Statistics and maternal infections 
reported by the National Hospital Register were used as markers of maternal infection during 
pregnancy. CP diagnoses were obtained from the Danish Cerebral Palsy Registry. Adjusted hazard 
ratio (HR) and 95% confidence interval (CI) were estimated by Cox proportional hazard models.
Results—Of the 440 564 singletons with follow-up data, 840 were diagnosed with congenital 
CP. Maternal genito-urinary tract infections (HR 2.1, 95% CI 1.4, 3.2) were associated with CP in 
all births, in term births (HR 1.9, 95% CI 1.1, 3.2), in children with spastic CP (HR 2.1, 95% CI 
1.4, 3.3), and among first-born children (HR 1.9, 95% CI 1.4, 3.3). Overall, we found associations 
between redeemed nitrofurantoin (HR 1.7, 95% CI 1.1, 2.8) and CP. Among trimester-specific 
exposures, CP risk was associated with prescriptions redeemed in the first trimester for any 
antibacterials, beta-lactam antibacterials, and nitrofurantoin, an antibiotic commonly used to treat 
lower urinary tract infection, and genito-urinary tract infections in the third trimester.
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Conclusion—Genito-urinary tract infections and antibiotic use during pregnancy were 
associated with increased risks of CP, indicating that some maternal infections or causes of 
maternal infections present in prenatal life may be part of a causal pathway leading to CP.
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Background
Cerebral palsy (CP) is one of the most common motor disabilities in childhood with 
prevalence estimates close to 2 per 1000 livebirths in Denmark.1,2 Fetal exposures during 
gestation, such as maternal infections, have been associated with an increased risk for CP 
and other neurological disorders in the child.3-10 Part of the immune response to infections is 
the possible increase of brain vulnerability, which may cause fetal white matter damage, 
identified as an important risk factor for the development of CP in preterm infants. 
Gestational age may modify the potential effect or act as a mediator on the causal pathway 
from infection to CP, inasmuch as intrauterine infection/inflammation has been identified as 
a cause of preterm delivery.12 Less is known about the potential effects in term infants.4,5
Neurological outcome studies often focus on inpatient hospital-diagnosed infections with 
less attention given to infections diagnosed by primary care doctors outside of hospitals, or 
in outpatient clinical settings. Prescription data, as a marker of infection, provide the ability 
to study infections not requiring hospitalisation otherwise excluded from hospital-based 
studies.
We hypothesised that exposure to some maternal infections during pregnancy may increase 
the risk of CP. We investigated a wide range of maternal infections or markers of maternal 
infections occurring during pregnancy in a population-based cohort.
Methods
Residents in Denmark are assigned a unique personal identification number that enables 
linkage of individual data among all national registries.13 From the Danish National Birth 
Registry we identified all liveborn singletons born in Denmark between January 1997 and 
December 2003 who were alive at birth and resided in Denmark up to December 2008 (n = 
442 370). Of these, 440 564 survived to 1 year after birth and were included in the analysis 
(Figure 1).
Exposure information
In Denmark, the general practitioner (GP) provides primary medical care but refers patients 
to a specialist or hospital, either for inpatient or for outpatient care, if conditions warrant 
specialised attention. GPs, other physicians, or dentists can prescribe medication and all 
pharmacy-redeemed prescriptions are recorded in a national prescription register.14 We 
identified maternal infections by two separate sources, the National Register of Medicinal 
Product Statistics (prescription registry) and the Danish National Hospital Register, in order 
to study a wide spectrum of maternal infections.
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The prescription registry was used to capture maternal infections treated with prescription 
antibiotics; infections treated only intravenously or during an inpatient hospital admission 
are not recorded in the registry. Data on type of infection, reason for prescription (treatment 
or prophylaxis), and actual use of medication are not available. The prescription registry 
contains individual-level information on all redeemed prescriptions in Denmark since 1994 
except on drugs sold without a prescription or drugs for inpatient use only. Drugs are coded 
according to the WHO Anatomical Therapeutic Chemical (ATC) classification system. ATC 
codes and date of sale for each prescription are stored when redeemed.
Antibiotics for the study were defined with the overall ATC code ‘J01’ (any systemic 
antibacterial), and the ATC subgroups ‘J01C’ (beta-lactam antibacterials, penicillins), ‘J01E’ 
(sulfonamides and trimethoprim), ‘J01F’ (macrolides, lincosamides, and streptogramins), 
and ‘J01X’ (other antibacterials). We investigated the specific antibiotics ‘J01CE02’ 
(phenoxymethylpenicillin) and ‘J01FA01’ (erythromycin) because of their frequent use, and 
‘J01CA08’ (pivmecillinam), ‘J01EB02’ (sulfamethizole, mono-therapy not in combination 
with trimethoprim), and ‘J01XE01’ (nitrofurantoin), which are used almost exclusively to 
treat uncomplicated lower urinary tract infections in Denmark.15
We categorised children as exposed to redeemed antibiotics during pregnancy if the mother 
redeemed a prescription for an aforementioned medication with the date of sale between the 
start of pregnancy and the date of birth of the child.
Hospital-reported maternal infections
The Danish National Hospital Register was used to capture all maternal infections diagnosed 
and treated during inpatient or outpatient hospital admission; information on diagnoses by 
GPs is not yet available. The register may include infections treated with either oral or 
intravenous medications. The register holds information on all discharges from Danish 
hospitals including outpatient treatments. Diagnostic information is based on the Danish 
version of the International Classification of Diseases, 10th revision (ICD-10), from 1994 
onward and reported to the register after each hospital visit.
We categorised children as exposed to hospital-reported maternal infections during 
pregnancy if the mother was recorded in the register with an ICD-10 code for a defined 
infection between the start of pregnancy and the date of birth of the child (see Appendix 1).
Cerebral palsy
Children’s CP status was ascertained from the Danish Cerebral Palsy Registry. Cohort 
members were identified as having validated congenital CP if alive after the first year of life 
and included in the registry. The population-based registry contains records of individuals 
with CP from the birth year 1925 and reported prevalence data since 1950 for part of the 
country.1 The registry covers the entire country from birth years 1997–2003. Case notes are 
collected from all paediatric departments and suspected cases of CP are validated based on a 
review of a child’s physical findings at the age of 5–6 years contained in medical records by 
trained child neurologists and obstetricians. Information including subtyping of CP is 
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registered in a standard format.1 Resolved conditions, progressive disorders, motor disorders 
attributable to spinal cord diseases, and cases with obvious post-perinatal aetiology are 
excluded from the registry. Time of onset was defined in the cohort as the first recorded date 
of diagnosis (i.e. the date diagnosis criteria were met), corresponding with the date parents 
were informed of a confirmed CP diagnosis. If the date of diagnosis occurred before the age 
of 1 because of a firm diagnosis (n = 209) or was missing (n = 17), the time of onset was 
defined as 1 year after the date of birth.
Covariates
Data on maternal age, gestational age at birth, sex, smoking status during pregnancy, mode 
of delivery, parity, and birth year were obtained from the Danish Medical Birth Registry. 
During the study years, data on gestational age at birth were estimated from ultrasound 
measures during early pregnancy, and if not available, the last menstrual date was used 
(<1%). Parental income was obtained from the Fertility Database, which contains annually 
collected education, employment, and family/housing information for people of fertile age in 
Denmark.16 Parental income was defined as the parents’ combined income during the 
child’s birth year; if missing for both parents, data from the previous calendar year were 
used if available.
Statistical analyses
We modelled the risk of CP in the children over time among different exposure groups 
during pregnancy. Children were categorised as unexposed if the mother did not have a 
redeemed prescription for any systemic antibiotic (ATC: J01) and did not have an ICD-10 
code for any of the defined infections between the start of pregnancy and the date of birth of 
the child. Initiation of pregnancy was calculated by subtracting gestational age in days from 
the date of birth. All children included in the analysis survived to 1 year of age and were 
followed until a reported diagnosis of CP in the Cerebral Palsy Registry, death, or December 
2008, whichever occurred first. Hazard ratio (HR) and 95% confidence interval (CI) were 
estimated by Cox proportional hazard models with person-years as the time-to-event 
variable and robust standard errors accounted for interdependency between multiple 
pregnancies of women during the study period [n = 103 582 mothers (31.5%) had multiple 
pregnancies]. Directed acyclic graphs17 provide a method for the evaluation of confounders 
and mediators, and were used to guide the selection of potential confounders to be 
controlled. Factors associated with an increased risk for CP as well as for infection were 
considered potential confounders; factors associated with an increased risk for CP but 
possibly affected by infection (mediators), i.e. intrauterine growth restriction, were not 
considered confounders. The final models included maternal age18 (<20, 20–24, 25–29, 30–
34, >= 35), smoking during pregnancy19 (yes, no), income during birth year20 (<300 000, 
300 000–500 000, and >500 000 Danish kroner), and the midpoint calendar year from all 
birth years2 (<2000 and ≥2000). Missing values for smoking and income (<5%) were 
included as distinct categories to maintain the sample size.
We performed a number of stratified analyses. First, to examine the potential modifying 
effect of gestational age on the association, we performed analyses among children born 
preterm (<37 weeks) or term (≥37 weeks), knowing that stratifying on a potential collider 
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variable could introduce bias by inducing otherwise controlled associations.21 Second, we 
restricted cases in our analysis to those with spastic CP, a common subtype that appears to 
be associated with intrauterine infection.22 Third, we categorised timing of maternal 
infection during pregnancy based on the trimester in which a prescription was redeemed or a 
defined ICD-10 code infection reported. The time of maternal infection was assigned to the 
trimester(s) in which a prescription was redeemed or an ICD code reported because the 
actual start and end date of the infections are not available. For each trimester, exposure 
groups were compared with the unexposed group used in the original analysis. Only children 
who were exposed during the trimester of interest were included in the trimester-specific 
analysis. One-third of children were exposed during multiple trimesters and included in the 
analysis for each exposed trimester. Fourth, we looked at the overall associations in firstborn 
children to eliminate possible bias related to behaviour modification induced by previous 
adverse pregnancy outcomes if a suspect prenatal exposure is considered harmful and is 
modifiable.23 Lastly, we categorised women by the number of redeemed prescriptions to 
examine the association of possible severity or length of maternal infection and CP. A 
stratified analysis by the number of hospital diagnoses was not performed because recurrent 
infections or the same infection recorded on different dates could not be distinguished in our 
data. Analyses were performed using PROC PHREG in SAS version 9.2 (SAS Institute, 
Cary, NC, USA). The study was approved by the Danish Data Protection Agency.
Results
Children were followed from 1 year to a maximum of 12 years of age (mean 8.5 years of 
age). A total of 840 children with CP were identified, of whom 86% (n = 720) had spastic 
CP. Exposure and case status are illustrated in Figure 1. Table 1 summarises characteristics 
of cohort children who had mothers exposed to any redeemed antibiotic or any hospital-
reported maternal infection during pregnancy. Thirty per cent of children had mothers with a 
redeemed antibiotic during pregnancy and 3% of children had mothers who had a hospital-
reported maternal infection; 6.7% of exposed children were exposed to mothers with both a 
redeemed antibiotic and a hospital-reported maternal infection during pregnancy. Women 
with hospital-reported maternal infections during pregnancy were slightly younger and had 
lower incomes, lower gestational age, more caesarean sections, and later birth years, and 
more reported they had smoked during pregnancy, compared with unexposed women.
Children of mothers with any redeemed antibiotic or hospital-reported maternal infection 
during pregnancy were more likely to have CP than unexposed children (Table 2). An 
increased risk of CP was observed with children whose mothers redeemed nitrofurantoin 
(HR 1.7, 95% CI 1.1, 2.8) and with hospital-reported maternal genito-urinary tract infection 
(HR 2.1, 95% CI 1.4, 3.2). Fewer than five CP cases had mothers with amniotic sac and 
membrane infections (results given in the table).
Among the subgroup of children of mothers exposed to both any redeemed antibiotic and 
any hospital-reported maternal infection during pregnancy, we observed an association with 
CP (HR 1.7, 95% CI 1.2, 2.5) (data not shown).
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Analysis of spastic CP cases revealed statistically significant associations between exposure 
to any hospital-reported maternal infection (HR 1.6, 95% CI 1.1, 2.2), hospital-reported 
maternal genito-urinary tract infections (HR 2.1, 95% CI 1.4, 3.3), and spastic CP (data not 
shown).
In the analyses stratified on gestational age, among unexposed children, the percentage of 
children born preterm with CP was 1.1% (154/13 717), notably higher than the percentage 
of children born term with CP (0.13%; 387/289 413) (Table 3). Among children born 
preterm, 32% were exposed to redeemed antibiotics and 9% to hospital-reported maternal 
infections during pregnancy, whereas in children born at term, 30% were exposed to 
redeemed antibiotics and 4% to hospital-reported maternal infections during pregnancy. 
Among children born preterm, no statistically significant associations were observed 
between hospital-reported maternal infections and the risk of CP; however, for some 
exposure groups, stratum-specific numbers were small and CI wide. Among children born at 
term, statistically significant associations with CP were observed among those exposed to 
any redeemed antibiotic, beta-lactam antibacterials, phenoxymethylpenicillin, and hospital-
reported maternal genito-urinary tract infection (Table 3).
When examining the timing of exposure, first trimester exposure to any redeemed antibiotic, 
betalactam antibacterials, or nitrofurantoins (other antibacterials were predominately 
nitrofurantoin) was associated with CP (Table 4, limited data presented). Exposures during 
the second or third trimester for these medications were not significantly associated with CP, 
although exposure to any redeemed antibiotic during the second trimester was significantly 
associated with CP (HR 1.3, 95% CI 1.1, 1.5). Third trimester diagnosis of any hospital-
reported maternal infections (HR 1.8, 95% CI 1.2, 2.8) and hospital-reported maternal 
genito-urinary tract infection (HR 2.5, 95% CI 1.6, 4.1) was associated with CP.
Our analysis in firstborn children showed associations between CP and exposure to 
redeemed nitrofurantoin (HR 2.3, 95% CI 1.3, 4.1) and hospital-reported genito-urinary 
infections (HR 1.9, 95% CI 1.1, 3.4) (data not shown).
Sixty-six per cent of women who redeemed antibiotics during pregnancy redeemed only one 
prescription and 34% redeemed >1 prescription during pregnancy. No additional risks 
associated with the redemption of >1 prescription were observed (any antibacterials HR 1.2, 
95% CI 0.9, 1.5) (data not shown).
Comment
Overall, we found CP to be associated with markers of maternal infection, specifically a 
redeemed prescription for any antibacterial medication or nitrofurantoin during pregnancy 
and hospital-reported maternal genito-urinary tract infections. These associations may be 
causal, indicators of causes (e.g. immune factors),24 or non-causal.
Several studies support relations between intrauterine infection and the development of 
periventricular leukomalacia,25-27 which is typically found in children with spastic CP, 
children who were preterm, and occasionally children who were term.28 The immune 
response to infections, including the release of cytokines, may be an aetiologic factor for 
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encephalopathy and possible CP leading to white matter brain damage by affecting fetal 
blood flow or the haemo-static system, coagulation necrosis of white matter,29 and increased 
permeability of the blood–brain barrier (facilitating microbial products and cytokines 
passing into the brain).30 Our associations of maternal infections with spastic CP are not 
new and are consistent with previous research.
Statistically significant associations between our markers for maternal infection and CP 
were not observed among children born preterm, which is expected if gestational age is an 
intermediate variable in the causal pathway. A higher exposure rate among preterm than 
term births supports maternal infection as a risk factor for preterm births, and the association 
between preterm birth and CP overall indicates that preterm birth could be a mediator, or 
modifier, of the association between maternal infection and CP. If so then our stratified 
analyses on preterm birth may hide the causal association of interest.
Several studies in preterm infants have examined the association between maternal infection 
with elevated cytokine levels and white matter damage in infants, but few studies exist in 
term infants that link elevated maternal cytokine levels to neurological disorders in the 
offspring.31 Our results in term children support such an association and are consistent with 
results from two population-based case-control studies: Neufeld et al. found an increased 
risk of CP among term infants of women with any infection during hospitalisation for 
delivery,5 and Grether and Nelson found an increased risk of CP in normal birthweight 
infants exposed to intrauterine maternal infection.7
Depending on the trimester, we found associations with particular markers for maternal 
infection and the risk of CP. Timing of infections may be an important component of fetal 
brain development, and our results indicate that some maternal infections may operate early 
in gestation; for example, chorioamnionitis may increase risk in the second trimester and be 
linked to preterm birth, whereas genito-urinary infections later in pregnancy may play a role 
in CP risk. Small strata and wide CI in this subanalysis affect our ability to know if other 
associations are present that could help clarify underlying associations between maternal 
infections in particular trimesters and CP. Our results on timing are only suggestive 
considering that the true onset of infection and the time of diagnosis may differ in that an 
infection could have been present for some time prior to presentation for care.
The frequency of genito-urinary tract infections in pregnancy,32 their proximity to the fetus, 
and their association with other childhood neurological outcomes9,33 provide reason for 
investigation in perinatal studies. The prescription data source does not include the 
indication for treatment; however, in Denmark nitrofurantoin, pivmecillinam, and 
sulfamethizole (monotherapy) (other sulfonamides and trimethoprim antibiotics are 
contraindicated in pregnancy34,35) are used almost exclusively to treat lower urinary tract 
infections and are not normally used for other indications during pregnancy.15 A comparison 
of these drugs, used for the same infection but with different mechanisms of action, may 
provide new information. The risk of CP associated with nitrofurantoin may suggest direct 
effects on the fetal brain, whereas the statistically non-significant risk associated with 
pivmecillinam and sulfamethizole may be attributable to better treatment effects, less severe 
underlying disease, or chance findings.
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We investigated all antibiotics on the Danish market, thus including a range of very different 
pharmacokinetic and dynamic antibiotics. If side effects from the antibiotics are responsible 
for the associations between antibiotics and CP, we may expect to see largely different 
associations across the antibiotics, corresponding to the different chemical structures. 
However, the relatively similar associations across different antibiotics seem more likely 
related to an underlying cause or infection.
Hospital-reported infection diagnoses suggest more severe infection compared with the 
prescription data; our results reflect this in that we see higher HRs for CP among children 
exposed to hospital-reported maternal infection. Lower HRs among the prescription data 
may reflect the antibiotic’s effect to treat infection, thus removing the causal factor and 
biasing estimates toward the null, or exposure misclassification. Misclassification (non-
differential or differential) of the prescription and hospital data is possible and could 
potentially bias our effect estimates in either direction. Misclassification of the prescription 
data could occur if women categorised as unexposed to antibiotics used antibiotics redeemed 
outside the pregnancy time period or if women categorised as exposed to antibiotics used 
them as prophylactic treatment or were misdiagnosed and never actually infected. Women 
with redeemed antibiotics may not take them, but this would only affect estimates if the 
underlying exposure differed from the categorised exposure. Misclassification of the hospital 
data may occur if women categorised as unexposed had undiagnosed infections (e.g. mild 
viral infections) or if women with diagnosed infections were actually uninfected. Women 
with complicated pregnancies may be seen more frequently than women without 
complications, which may increase their likelihood of being diagnosed with an infection or 
of receiving prophylactic antibiotics. Given our method of identifying maternal infections, 
some of these misclassifications and biases are unavoidable. To potentially reduce some 
bias, we considered the number of redeemed prescriptions, assuming >1 may indicate actual 
use or infection and therefore a better marker of maternal infection. No additional risk was 
observed among the 30% of women with >1 redeemed prescription.
Our study has several strengths, including well-maintained population-based registries, 
minimal loss to follow-up, well-documented redeemed prescription data, reliable 
hospitalisation information, and physician-validated CP cases. The use of data collected for 
non-research purposes may reduce the risk of differential misclassification. Redeemed 
prescription data provides the ability to study indication-specific antibiotics and an expanded 
exposure group that includes non-hospitalised maternal infections. In terms of limitations, 
subclinical maternal infections or infections not requiring hospitalisation or prescribed 
antibiotics may not have been captured in our data sources. The small number of exposed 
cases for some of the strata limits interpretation of the findings. Children must survive 1 year 
of age to be included in the CP registry. Therefore, our results are conditional on survival 
past 1 year, which would bias results if a disproportionate amount of potential CP cases, as 
compared with children without CP, do not survive 1 year of age, a condition that at present 
cannot be confirmed. We could not adjust for unknown or unmeasured social and biological 
factors that may explain some of the increased risk.
This study supports that certain maternal infections during pregnancy and their causes or 
consequences may have a potential effect on fetal brain development.36 Our results reflect 
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the complexity of the aetiologic processes leading from infection to CP. Future research 
should explore the timing of exposure to infection, a larger set of specific biomarkers of 
infections, and information on indirect conditions linked to infections.
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Appendix 1 - Definitions of infection categories based on ICD-10 codes
Any hospital infection during pregnancy Includes all following ICD-10 
codes
Certain infectious and parasitic diseases (generally recognised as communicable or
 transmissible diseases)
A00-B99
Infections of genito-urinary tract in pregnancy O23
Maternal infectious and parasitic diseases classifiable elsewhere but complicating
 pregnancy, childbirth, and the peurperium
O98
Infection of amniotic sac and membranes O41.1
All other hospital infections (eye, ear, central nervous system, upper airway,
 pneumonia, etc.)
See below table
Complete list of ‘all other infectionsȉ category:
Infection in the central nervous system G00-G02, G04-G07
Eye infections H00-H01, H03, H040, H043, H10, H16
Ear infections H60, H62, H65-H68, H70, H75
Upper airway infections J00-J06
Pneumonia and influenza J09-J18, J20-J22
Abscess in thorax J85-J86







Infections of joints (excluding common inflammatory) M00-M01
Infective myositis M600
Osteomyelitis M860-M862, M869
Kidney infections N10, N129
Cystitis N30
Genital infections N70-N77
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Exposure and case status of the study population. The exposure classification and case status 
of the study population is presented as a flow chart with a table of the exposure classification 
of children with cerebral palsy.
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Table 1
Baseline characteristics of all children born in Denmark from 1997 to 2003 who survived to 1 year of age, 






Characteristic Number % Number % Number %
Gender
 Male 155 535 51 67 500 51 7 679 51
 Female 147 595 49 64 174 49 7 257 49
 Missing 0 0 0 0 0 0
Gestational age (weeks)
 <37 13 717 5 6 374 5 1 300 9
 37–42 263 282 87 114 283 87 12 602 84
 ≥42 26 131 9 11 017 8 1 034 7
 Missing 0 0 0 0 0 0
Income
a
 Low 50 782 17 25 345 19 3 832 26
 Medium 135 232 45 59 955 46 6 407 43
 High 110 522 36 42 885 33 4 072 27
 Missing 6 594 2 3 489 3 625 4
Maternal age (years)
 <20 4 265 1 2 818 2 592 4
 20–24 37 711 12 19 538 15 3 038 20
 25–29 111 563 37 46 648 35 5 134 34
 30–34 104 080 34 43 746 33 4 326 29
 ≥35 45 511 15 18 924 14 1 846 12
 Missing 0 0 0 0 0 0
Smoking during pregnancy
 No 231 393 76 92 757 70 10 064 67
 Yes 58 750 19 33 082 25 4 078 27
 Missing 12 987 4 5 835 4 794 5
Caesarean delivery
 No 246 446 81 104 572 79 11 275 75
 Yes 56 684 19 27 102 21 3 661 25
 Missing 0 0 0 0 0 0
Birth year
 1997–1999 133 263 44 55 816 42 5 829 39
 2000–2003 169 867 56 75 858 58 9 107 61
 Missing 0 0 0 0 0 0
The exposure groups are not mutually exclusive and may include overlap; see the Results section for the exact percent.
a
Low income was defined as <300 000 Danish kroner, middle income as 300 000–500 000, and high income as >500 000.
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Table 2
Hazard ratios (HR) for cerebral palsy (CP) according to markers of infection during pregnancy






 Unexposed 303 130 541 1.0 [Reference]
 Any antibacterial for systemic use 131 674 285 1.2 [1.0, 1.4]
 Beta-lactam antibacterials 102 279 212 1.2 [1.0, 1.4]
  Phenoxymethylpenicillin 58 525 124 1.2 [1.0, 1.4]
  Pivmecillinam
b 27 703 50 1.0 [0.8, 1.4]
 Sulfonamides and trimethoprim 29 895 70 1.3 [1.0, 1.6]
  Sulfamethizole, mono therapy
b 29 679 70 1.3 [1.0, 1.6]
 Macrolides, lincosamides, and streptogramins 15 235 35 1.3 [0.9, 1.8]
  Erythromycin 11 734 25 1.2 [0.8, 1.7]
 Other antibacterials 5 516 16 1.6 [1.0, 2.7]
  Nitrofurantoin 
b 5 403 16 1.7 [1.1, 2.8]
Hospital-reported maternal infections
 Unexposed 303 130 541 1.0 [Reference]
 Any hospital-reported maternal infection 14 936 42 1.6 [1.1, 2.1]
 Certain infectious and parasitic diseases (A00-B99)
c 3 284 6 1.0 [0.4, 2.2]
 Infections of genito-urinary tract in pregnancy (O23) 6 231 24 2.1 [1.4, 3.2]
 Maternal infectious and parasitic diseases classifiable elsewhere but
   complicating pregnancy, childbirth, and the peurperium (O98)
406 1 1.4 [0.2, 9.7]
 Infection of amniotic sac and membranes (O41.1) 260 2 4.0 [1.0, 16.1]
 All other hospital infections (eye, ear, central nervous system upper
   airway, pneumonia, etc.)
6 027 11 1.0 [0.5, 1.8]
a
Adjusted HR adjusted for maternal age, smoking during pregnancy, parental income during birth year, and calendar year.
b
Medications commonly used for treatment of lower urinary tract infection in Denmark.15
c
Includes diseases generally recognised as communicable or transmissible according to the International Classification of Diseases, 10th revision.
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Table 3
Hazard ratios (HR) for cerebral palsy (CP) among preterm or term infants according to markers of infection 
during pregnancy
Preterm delivery Term delivery
Total N CP cases HR
a




 Unexposed 13 717 154 1.0 [Reference] 289 413 387 1.0 [Reference]
 Any antibacterial for systemic use 6 374 79 1.1 [0.8, 1.4] 125 300 206 1.2 [1.0, 1.4]
 Beta-lactam antibacterials 4 850 52 1.0 [0.7, 1.3] 97 429 160 1.2 [1.0, 1.5]
  Phenoxymethylpenicillin 2 670 29 1.0 [0.6, 1.5] 55 855 95 1.3 [1.0, 1.6]
  Pivmecillinam
b 1 315 14 1.0 [0.6, 1.7] 26 388 36 1.0 [0.7, 1.5]
 Sulfonamides and trimethoprim 1 560 26 1.5 [1.0, 2.2] 28 335 44 1.1 [0.8, 1.6]
  Sulfamethizole, mono therapy
b 1 546 26 1.5 [1.0, 2.2] 28 133 44 1.1 [0.8, 1.6]
 Macrolides, lincosamides, and streptogramins 778 9 1.0 [0.5, 2.0] 14 457 26 1.3 [0.9, 2.0]
  Erythromycin 591 8 1.2 [0.6, 2.4] 11 143 17 1.1 [0.7, 1.8]
 Other antibacterials 269 4 1.4 [0.5, 3.7] 5 247 12 1.7 [1.0, 3.1]
  Nitrofurantoin
b 260 4 1.4 [0.5, 3.8] 5 143 12 1.8 [1.0, 3.1]
Hospital-reported maternal infections
 Unexposed 13 717 154 1.0 [Reference] 289 413 387 1.0 [Reference]
 Any hospital-reported maternal infection 1 300 20 1.4 [0.9, 2.2] 13 636 22 1.2 [0.8, 1.8]
 Certain infectious and parasitic diseases (A00-B99)
c 214 3 1.2 [0.4, 3.8] 3 070 3 0.7 [0.2, 2.3]
 Infections of genito-urinary tract in pregnancy (O23) 645 10 1.4 [0.7, 2.7] 5 586 14 1.9 [1.1, 3.2]
 Maternal infectious and parasitic diseases classifiable
   elsewhere but complicating pregnancy, childbirth,
   and the peurperium (O98)
32 1 3.0 [0.4, 20.4] 374 0 -
 Infection of amniotic sac and membranes (O41.1) 142 2 1.2 [0.3, 4.9] 118 0 -
 All other hospital infections (eye, ear, central nervous
   system, upper airway, pneumonia, etc.)
431 5 1.0 [0.4, 2.5] 5 596 6 0.8 [0.4, 1.8]
CI, confidence interval.
a
Adjusted HR adjusted for maternal age, smoking during pregnancy, parental income during birth year, and calendar year.
b
Medications commonly used for treatment of cystitis in Denmark.15
c
Includes diseases generally recognised as communicable or transmissible according to the International Classification of Diseases, 10th revision.
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Table 4
Hazard ratios (HR) for cerebral palsy (CP) among all children according to trimester of exposure for any 
redeemed antibiotic and any hospital-reported maternal infection during pregnancy
First trimester Second trimester Third trimester
Total N CP cases HR
a
 (95% CI) Total N CP cases HR
a
 (95% CI) Total N CP cases HR
a
 (95% CI)
Unexposed 303 130 541 1.0 [Reference] 303 130 541 1.0 [Reference] 303 130 541 1.0 [Reference]
Any antibacterial for
 systemic use
52 707 129 1.3 [1.1, 1.6] 62 878 143 1.3 [1.1, 1.5] 48 798 88 1.0 [0.8, 1.3]
Any hospital-reported
 maternal infection
3 663 9 1.4 [0.7, 2.6] 6 487 17 1.4 [0.9, 2.3] 6 913 23 1.8 [1.2, 2.8]
Children who were not exposed during the trimester of interest were excluded from the analysis for that specific trimester. Children born before the 
third trimester were not included in the third trimester analysis. Children may have been exposed for more than one trimester.
CI, confidence interval.
a
Adjusted HR adjusted for maternal age, smoking during pregnancy, parental income during birth year, and calendar year.
Paediatr Perinat Epidemiol. Author manuscript; available in PMC 2016 August 25.
